Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials
MJ Maurer, TM Habermann, Q Shi, N Schmitz, D Cunningham, M Pfreundschuh, JF Seymour, U Jaeger, C Haioun, H Tilly, H Ghesquieres, F Merli, M Ziepert, R Herbrecht, J Flament, T Fu, CR Flowers, B Coiffier
Annals of Oncology | OXFORD UNIV PRESS | Published : 2018
Awarded by National Institutes of Health University of Iowa/Mayo Clinic Lymphoma SPORE
This work was supported by grants from Celgene Corporation. Data were transmitted directly from original study cooperative groups to the Mayo Clinic. Celgene Corporation supported organization and meetings of the SEAL group. The National Institutes of Health University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274) grant provided support for MJM and TMH.